dsp-7888
Vaccineexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2015 (NCT02436252)
Timeline
Indications
Studied for
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Carcinoma, Renal Cell · Phase 1
- Carcinoma, Transitional Cell · Phase 1
- Diffuse Intrinsic Pontine Glioma · Phase 1/Phase 2
- Fallopian Tube Neoplasms · Phase 1
- Glioblastoma · Phase 1/Phase 2
- Hamartoma · Phase 1
- Leukemia, Myeloid, Acute · Phase 2
- Melanoma · Phase 1
- Myelodysplastic Syndromes · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 1
- Sarcoma · Phase 1
Mechanism of action
- Wilms tumor proteinImmunity, active
immunity, active - wt1
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- dsp-7888
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04747002 | Phase 2 | Jun 12, 2020 | Japan Agency for Medical Research and Development, Osaka University |
| NCT03311334 | Phase 1 | Dec 14, 2017 | Boston Biomedical |
| NCT02750891 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2016 | Sumitomo Dainippon |
| NCT02498665 | Phase 1 | Nov 1, 2015 | Boston Biomedical |
| NCT02436252 | Phase 1/Phase 2 (Phase 2) | May 1, 2015 | Sumitomo Dainippon |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boston Biomedical | For profit | 2 | 2 | 1 | 2015 |
| Sumitomo Dainippon | For profit | 2 | 2 | 1 | 2015 |
| Japan Agency for Medical Research and Development | Government | 1 | 0 | 1 | 2020 |
| Osaka University | Academic/Hospital | 1 | 1 | 1 | 2020 |
4 organizations
Page 1 / 1